

QUANTITY LIMIT CRITERIA

BRAND NAME
(generic)

CINVANTI (ALL PRODUCTS)
(aprepitant)

EMEND (ALL PRODUCTS)
(aprepitant)

EMEND (ALL PRODUCTS)
(fosaprepitant dimeglumine)

VARUBI (ALL PRODUCTS)
(rolapitant)

Status: CVS Caremark Criteria

Type: Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Cinvanti (aprepitant) injectable emulsion

Cinvanti, in combination with other antiemetic agents, is indicated in adults for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use

- Cinvanti has not been studied for the treatment of established nausea and vomiting.

Emend (aprepitant) capsules and oral suspension

Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

Emend for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Emend capsules, in combination with other antiemetic agents, is indicated in patients 12 years of age and older for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Emend, Cinvanti, Varubi Limit Policy 01-2018

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). © Registered trademark of the Blue Cross and Blue Shield Association

Prevention of Postoperative Nausea and Vomiting (PONV)

Emend capsules are indicated in adults for the prevention of postoperative nausea and vomiting.

Limitations of Use

- Emend has not been studied for the treatment of established nausea and vomiting.
- Chronic continuous administration of Emend is not recommended because it has not been studied and because the drug interaction profile may change during chronic continuous use.

Emend (fosaprepitant dimeglumine) for injection

Emend for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of:

- acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
- delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use

- Emend has not been studied for the treatment of established nausea and vomiting.

Varubi

Varubi is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

REFERENCES

1. Cinvanti [package insert]. San Diego, CA: Heron Therapeutics, Inc.; November 2017.
2. Emend capsules and oral suspension [package insert]. Whitehouse Station, NJ: Merck and Co., Inc; May 2017.
3. Emend for injection [package insert]. Whitehouse Station, NJ: Merck and Co., Inc; August 2017.
4. Varubi [package insert]. Waltham, MA: Tesaro, Inc; October 2017.
5. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed January 2018.
6. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed January 2018.
7. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Antiemesis. V.2.2017. Available at: www.nccn.org. Accessed January 2018.

LIMIT CRITERIA

The initial quantity limit for Cinvanti and Emend is sufficient to treat 2 chemotherapy cycles per month.

Drug	4 Weeks Limit and 12 Weeks Limit*
Cinvanti 130 mg Vial	2 vials / 21 days
Emend 80 mg Capsule	4 capsules / 21 days
Emend 125 mg Capsule	2 capsule / 21 days
Emend Tri-pack (contains one 125 mg capsule and two 80 mg capsules)	2 packs / 21 days
Emend 125 mg for Oral Suspension (Single-Dose Kit)	6 kits / 21 days

Emend 150 mg Injection

2 vials / 21 days

Emend 40 mg capsule

3 capsules / 6 months

**** This drug is indicated for short-term acute use; therefore, the mail limit will be the same as the retail limit. The duration of 21 days is used for a 28-day fill period.***

LIMIT CRITERIA

The initial quantity limit for Varubi is sufficient to treat 2 chemotherapy cycles per month (each cycle given at no less than 2-week intervals); therefore, no additional quantities are available through a post limit document.

Drug	4 Weeks Limit and 12 Weeks Limit*
Varubi single dose package (contains two 90 mg tablets as one set of twinned blisters)	2 packs/ 21 days
Varubi Injectable Emulsion (each vial delivers 166.5 mg / 92.5 ml)	2 vials/ 21 days

**** This drug is indicated for short-term acute use; therefore, the mail limit will be the same as the retail limit. The duration of 21 days is used for a 28-day fill period.***